Advances have been made in the last years in metastatic colorectal cancer treatments, with the introduction of novel molecularly targeted agents like antibodies against the VEGF or the EGFR targets; nonetheless rate of long survivors are low. This evidence concerns the gene VEGFA and metastatic colorectal cancer.